PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study | Synapse
April 18, 2026Open Access
PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study
Puntos clave
This research examines how PCSK9 inhibitors affect outcomes in ASCVD patients who have not experienced previous ischaemic events.
Conducted an observational study
Analyzed clinical practice data
Compared outcomes of patients treated with PCSK9 inhibitors against those not receiving the treatment.
Patients treated with PCSK9 inhibitors had lower ischaemic event rates.
Mortality rates were also reduced in patients receiving treatment.
Resumen
In ASCVD patients without prior events in clinical practice, PCSK9i mAb treatment was associated with lower ischaemic event and mortality rates.